Short answer
Elevance Health (ELV) filed an 8-K current report with the SEC on March 10, 2026 reporting Item 7.01 (Regulation FD Disclosure). ELV reaffirms 2026 adjusted EPS guidance of at least $25.50 per diluted share, already factoring in potential CMS Medicare Advantage enrollment sanctions.
Elevance Health 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- ELV reaffirms 2026 adjusted EPS guidance of at least $25.50 per diluted share, already factoring in potential CMS Medicare Advantage enrollment sanctions
- 2026 benefit expense ratio guidance reaffirmed at 90.2% ±50 bps: a high ratio signaling continued cost pressure in the medical segment
- CMS sanctions (effective March 31, 2026) suspend new Medicare Advantage-PD enrollment and certain beneficiary communications: material top-line risk to Medicare growth
- Company cannot reconcile adjusted to GAAP EPS "without unreasonable effort": signals potential material financial payments to resolve CMS matter remain unquantified
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Elevance Health 8-K filings
Get the next ELV 8-K as it lands
Follow ELV for push alerts, or ask the research agent what this filing means.